LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.24 -2.36

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.22

Máximo

1.28

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Vender
Estimación a 12 Meses	+57.48% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-24M 78M
Apertura anterior	3.6
Cierre anterior	1.24

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 mar 2026, 18:43 UTC

Noticias de Eventos Importantes

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3 mar 2026, 17:33 UTC

Adquisiciones, fusiones, absorciones

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3 mar 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3 mar 2026, 23:44 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3 mar 2026, 23:25 UTC

Charlas de Mercado

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3 mar 2026, 23:25 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

3 mar 2026, 22:38 UTC

Noticias de Eventos Importantes

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3 mar 2026, 22:16 UTC

Ganancias

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3 mar 2026, 22:09 UTC

Ganancias

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3 mar 2026, 22:06 UTC

Ganancias

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3 mar 2026, 22:05 UTC

Ganancias

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3 mar 2026, 22:03 UTC

Ganancias

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Tech, Media & Telecom Roundup: Market Talk

3 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

3 mar 2026, 21:45 UTC

Noticias de Eventos Importantes

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3 mar 2026, 21:37 UTC

Ganancias

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3 mar 2026, 21:26 UTC

Noticias de Eventos Importantes

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3 mar 2026, 20:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3 mar 2026, 20:04 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold and Silver Drop as Energy Surges -- Market Talk

3 mar 2026, 18:43 UTC

Ganancias

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3 mar 2026, 18:29 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Energy Roundup: Market Talk

3 mar 2026, 18:29 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3 mar 2026, 18:22 UTC

Noticias de Eventos Importantes

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3 mar 2026, 18:22 UTC

Noticias de Eventos Importantes

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3 mar 2026, 18:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3 mar 2026, 18:14 UTC

Ganancias

How Long Can Anthropic Play Defense? -- WSJ

3 mar 2026, 17:41 UTC

Noticias de Eventos Importantes

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3 mar 2026, 17:28 UTC

Adquisiciones, fusiones, absorciones

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

57.48% repunte

Estimación a 12 Meses

Media 2 USD 57.48%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.